Structure Therapeutics Advances Weight-Loss Pills With New Clinical Data
Structure Therapeutics (NASDAQ: GPCR) reports strong clinical trial data for oral weight loss candidates ACCG-2671 and aleniglipron.
Stocks · News reference
Citizens Reiterates Market Outperform on Structure Therapeutics, Maintains $110 Price Target
Citizens analyst Jonathan Wolleben reiterates Structure Therapeutics (NASDAQ:GPCR) with a Market Outperform and maintains $110 price target.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Novo Nordisk's Semaglutide Meets Goal in Pediatric Obesity Study
Novo Nordisk announced positive phase III STEP Young study results showing semaglutide reduced BMI in children aged 6-12 with obesity, with 40.4% no longer classified as obese after 68 weeks. However, the company faces mounting competitive pressure from Eli Lilly's superior weight-loss drugs and emerging biotech competitors in the GLP-1 obesity treatment market.
8-K filing — Structure Therapeutics Inc. (GPCR)
Filed: 2026-09-08 AccNo: 0001104659-26-105688 Size: 7 MB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits